findmyKOL
Clinical trialNCT02609503CompletedPhase 2Interventional

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

SponsorUNC Lineberger Comprehensive Cancer CenterEnrollment29Head and Neck Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • John Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 May 2016
Primary completion
23 Dec 2019
Completion
20 Nov 2023
Last update posted
5 Nov 2024
Registered enrollment
29
Registry id
NCT02609503

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.